BACKGROUND: Statins are some of the most commonly prescribed medications in medical practice, and prostate cancer is the most common malignancy among men. Although there has been no consistent evidence that statins affect cancer incidence, including prostate cancer, several reports suggest they may decrease the rate of advanced prostate cancer. However, no study to date has specifically examined statin use and prostate cancer mortality. The authors conducted this population-based case-control investigation to examine this association. METHODS: This was a matched case-control study. Cases were residents of New Jersey ages 55 to 79 years who died from prostate cancer between 1997 and 2000. The cases were matched individually to population-based controls by 5-year age group and race. Medication data were obtained identically for cases and controls from blinded medical chart review. Conditional logistic regression was used to adjust for confounders. RESULTS: In total, 718 cases were identified, and cooperation was obtained from 77% of their spouses (N = 553). After a review of medical records, 387 men were eligible, and 380 were matched to a control. The unadjusted odds ratio was 0.49 (95% confidence interval, 0.34-0.70) and decreased to 0.37 (P < .0001) after adjusting for education, waist size, body mass index, comorbidities, and antihypertensive medication. There was little difference between lipophilic and hydrophilic statins, but more risk reduction was noted for high-potency statins (73%; P < .0001) compared with low-potency statins (31%; P = .32). CONCLUSIONS: Statin use was associated with substantial protection against prostate cancer death, adding to the epidemiologic evidence for an inhibitory effect on prostate cancer.
BACKGROUND: Statins are some of the most commonly prescribed medications in medical practice, and prostate cancer is the most common malignancy among men. Although there has been no consistent evidence that statins affect cancer incidence, including prostate cancer, several reports suggest they may decrease the rate of advanced prostate cancer. However, no study to date has specifically examined statin use and prostate cancer mortality. The authors conducted this population-based case-control investigation to examine this association. METHODS: This was a matched case-control study. Cases were residents of New Jersey ages 55 to 79 years who died from prostate cancer between 1997 and 2000. The cases were matched individually to population-based controls by 5-year age group and race. Medication data were obtained identically for cases and controls from blinded medical chart review. Conditional logistic regression was used to adjust for confounders. RESULTS: In total, 718 cases were identified, and cooperation was obtained from 77% of their spouses (N = 553). After a review of medical records, 387 men were eligible, and 380 were matched to a control. The unadjusted odds ratio was 0.49 (95% confidence interval, 0.34-0.70) and decreased to 0.37 (P < .0001) after adjusting for education, waist size, body mass index, comorbidities, and antihypertensive medication. There was little difference between lipophilic and hydrophilic statins, but more risk reduction was noted for high-potency statins (73%; P < .0001) compared with low-potency statins (31%; P = .32). CONCLUSIONS: Statin use was associated with substantial protection against prostate cancer death, adding to the epidemiologic evidence for an inhibitory effect on prostate cancer.
Authors: H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza Journal: Cancer Res Date: 2000-03-15 Impact factor: 12.701
Authors: Margaret D Carroll; David A Lacher; Paul D Sorlie; James I Cleeman; David J Gordon; Michael Wolz; Scott M Grundy; Clifford L Johnson Journal: JAMA Date: 2005-10-12 Impact factor: 56.272
Authors: Patricia F Coogan; Lynn Rosenberg; Julie R Palmer; Brian L Strom; Ann G Zauber; Samuel Shapiro Journal: Epidemiology Date: 2002-05 Impact factor: 4.822
Authors: J A Gordon; A Midha; A Szeitz; M Ghaffari; H H Adomat; Y Guo; T L Klassen; E S Guns; K M Wasan; M E Cox Journal: Prostate Cancer Prostatic Dis Date: 2015-08-04 Impact factor: 5.554
Authors: Melissa A Babcook; Sanjeev Shukla; Pingfu Fu; Edwin J Vazquez; Michelle A Puchowicz; Joseph P Molter; Christine Z Oak; Gregory T MacLennan; Chris A Flask; Daniel J Lindner; Yvonne Parker; Firouz Daneshgari; Sanjay Gupta Journal: Mol Cancer Ther Date: 2014-08-13 Impact factor: 6.261
Authors: June M Chan; Stacey A Kenfield; Alan Paciorek; Elizabeth A Platz; Edward L Giovannucci; Meir J Stampfer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-19 Impact factor: 4.254
Authors: June M Chan; Stephanie Litwack-Harrison; Scott R Bauer; Nicholas A Daniels; Timothy J Wilt; Jackilen Shannon; Douglas C Bauer Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-08-09 Impact factor: 4.254
Authors: Alison M Mondul; Corinne E Joshu; John R Barber; Anna E Prizment; Nrupen A Bhavsar; Elizabeth Selvin; Aaron R Folsom; Elizabeth A Platz Journal: Cancer Prev Res (Phila) Date: 2018-10-16